Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance

Medicine & Life Sciences

• Sitagliptin Phosphate 87%
• Glucose Intolerance 64%
• HIV 42%
• Inflammation 36%
• Placebos 26%
• CXC Chemokines 19%
• Protein C 17%
• Mucins 16%
• Epidermal Growth Factor 14%
• Glucose 14%
• C-Reactive Protein 13%
• Monocyte Chemoattractant Proteins 12%
• Hormones 10%
• Dipeptidyl Peptidase 4 10%
• Dipeptidyl-Peptidase IV Inhibitors 10%
• Chemokine CCL2 8%
• Hyperinsulinism 8%
• Cell Surface Receptors 8%
• Glucose Tolerance Test 7%
• Vascular Diseases 7%
• HIV Infections 6%
• Adipose Tissue 6%
• Insulin Resistance 6%
• Area Under Curve 6%
• Fasting 6%
• Leukocytes 6%
• Anti-Inflammatory Agents 5%
• Myocardial Infarction 5%
• Enzyme-Linked Immunosorbent Assay 5%
• Stroke 5%
• Health Care Outcome Assessment 5%
• Messenger RNA 4%
• Therapeutics 3%
• Incidence 3%

Chemistry

• Sitagliptin 100%
• Glucose 45%
• Antiretroviral 32%
• Chemotactic 20%
• Hormone 15%
• Marker 13%
• Dipeptidyl Peptidase IV Inhibitor 11%
• Area Under the Curve 10%
• Plasma 9%
• Insulin Derivative 7%
• Antiinflammatory 7%
• Protein 6%